Update
$Immutep(IMMP.US$ Initial Clinical Data Reported From Immutep's Efti Combined With Radiotherapy And Checkpoint Inhibitor From Phase II Trial In Soft Tissue Sarcoma
Benzinga· 2 mins ago
Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trial
Four of six patients treated have very good, near-complete pathologic responses (primary endpoint of study) that are rarely observed with standard therapies
Soft tissue sarcoma is a hard-to-treat orphan disease with poor prognosis & high unmet medical need
Additional data from EFTISARC-NEO planned for a medical conference in H2 CY2024
Benzinga· 2 mins ago
Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trial
Four of six patients treated have very good, near-complete pathologic responses (primary endpoint of study) that are rarely observed with standard therapies
Soft tissue sarcoma is a hard-to-treat orphan disease with poor prognosis & high unmet medical need
Additional data from EFTISARC-NEO planned for a medical conference in H2 CY2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
